País: Armènia
Idioma: anglès
Font: Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում
dimetindene (dimetindene maleate)
Novartis Consumer Health S.A.
R06AB03
dimetindene (dimetindene maleate)
1mg/ml
drops oral (solution)
glass bottle 20ml
OTC
Registered
2019-02-26
1 Regulatory Affairs FENISTIL® 1 MG/ML ORAL DROPS Dimethindene maleate SUMMARY OF PRODUCT CHARACTERISTICS Author: Manuela Bezzi Document type: SPC Document status: Final Release date: 13 September, 2005 Number of pages: 7 Property of Novartis Consumer Health SA Confidential May not be used, divulged, published or otherwise disclosed without the consent of Novartis Consumer Health SA 2 TABLE OF CONTENTS 1. NAME OF THE MEDICINAL PRODUCT .................................................................... 3 2. QUALITATIVE AND QUANTITATIVE COMPOSITION ................................. 3 3. PHARMACEUTICAL FORM. .......................................................................... 3 4. CLINICAL PARTICULARS ............................................................................... 3 4.1 Therapeutic indications. ....................................................................................... 3 4.2. Posology and method of administration ................................................................ 3 4.3. Contra-indications ................................................................................................ 4 4.4. Special warnings and special precautions for use .................................................. 4 4.5. Interactions with other medicinal products and other forms of interaction. ........... 4 4.6. Pregnancy and lactation. ...................................................................................... 4 4.7. Effects on ability to drive and use machines. ........................................................ 5 4.8. Undesirable effects. ............................................................................................. 5 4.9. Overdose .............................................................................................................. 5 5. PHARMACOLOGICAL PROPERTIES. ............................................................ 5 5.1. Pharmacodynamic properties ................................................................................ 5 5.2. Pharm Llegiu el document complet